The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden

被引：6
|
作者：
P. Lindgren
B. Jönsson
J. DuChane
机构：
[1] Stockholm Health Economics Consulting,
[2] Uppsala,undefined
[3] Sweden,undefined
[4] Stockholm School of Economics,undefined
[5] Stockholm,undefined
[6] Sweden,undefined
[7] Pharmacia Corporation,undefined
[8] Kalamazoo,undefined
[9] Mich.,undefined
[10] USA,undefined
来源：
The European Journal of Health Economics | 2003年 / 4卷 / 1期
关键词：
Keywords Parkinson's disease; Cost effectiveness; Decision modeling;
D O I：
10.1007/s10198-002-0144-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：37 / 42
页数：5
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF HYPERTENSION TREATMENT IN SWEDEN
    JOHANNESSON, M
    [J]. PHARMACOECONOMICS, 1995, 7 (03) : 242 - 250
  • [2] THE COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE COMPARED TO OLANZAPINE PAMOATE IN THE TREATMENT OF SCHIZOPHRENIA IN SWEDEN
    Pudas, H.
    Hemels, M.
    Mehnert, A.
    Druais, S.
    Martin, M.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A560 - A561
  • [3] Cost-effectiveness of treating restless legs patients with pramipexole compared to no treatment in Sweden
    Lees, M.
    Roberts, G.
    Tabberer, M.
    Bjorkman, J.
    Ulfberg, J.
    Finnern, H.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A376 - A376
  • [4] Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
    Knight, Christopher
    Mauskopf, Josephine
    Ekelund, Mats
    Singh, Amitabh
    Yang, Shiyi
    Boggs, Robert
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (02): : 145 - 156
  • [5] COST-EFFECTIVENESS OF COMPLYING WITH TREATMENT GUIDELINES IN SWEDEN
    Jonsson, E.
    Hansson-Hedblom, A.
    Ljunggren, O.
    Akesson, K.
    Spangeus, A.
    Borgstrom, F.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S440 - S440
  • [6] Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
    Christopher Knight
    Josephine Mauskopf
    Mats Ekelund
    Amitabh Singh
    Shiyi Yang
    Robert Boggs
    [J]. The European Journal of Health Economics, 2012, 13 : 145 - 156
  • [7] Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease
    Verschuur, Constant V. M.
    Suwijn, Sven R.
    de Haan, Rob J.
    Boel, Judith A.
    Post, Bart
    Bloem, Bas R.
    van Hilten, Johannes J.
    van Laar, Teus
    Tissingh, Gerrit
    Munts, Alexander
    Dijkgraaf, Marcel G. W.
    de Bie, Rob M. A.
    [J]. JOURNAL OF PARKINSONS DISEASE, 2022, 12 (07) : 2171 - 2178
  • [8] Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
    Kobelt, G.
    Berg, J.
    Lindgren, P.
    Jonsson, B.
    Stawiarz, L.
    Hillert, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (05) : 679 - 690
  • [9] Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared to current standard practice in Sweden
    Kobelt, G.
    Berg, J.
    Lindgren, P.
    Hillert, J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A239 - A240
  • [10] COST-EFFECTIVENESS OF EXTENDED ADJUVANT TREATMENT WITH LETROZOLE IN SWEDEN
    Lundkvist, J.
    Lindman, H.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A471 - A471
12345